Description
Tirzepatide is a dual agonist that targets both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, amplifying the effects of both incretin hormones. This dual action enhances insulin secretion, reduces glucagon levels, and improves glucose regulation more effectively than single-pathway agonists. Additionally, GLP-1 T’s influences metabolic signaling pathways to support energy balance and lipid metabolism, contributing to improved nutrient processing and storage.
